Download 61 daftar pustaka

DAFTAR PUSTAKA
Aguilar, F.M., Aguirre, C.M.L., Rocha, J.C.M., Chavez, J.A., Trevino, V., Padilla, C.R.,
Perez, D.R. 2013. Differential expression of miR-21, miR-125b and miR-191 in breast
cancer tissue. Asia-Pac J Clin Oncol 9: 53–59.
American
Type
Culture
Collection
(ATCC).
2014.
http://www.atcc.org/products/all/HTB-22.aspx#characteristics.[15 April 2014].
Aryandono, T. 2006. Faktor Prognosis Kanker Payudara Operable di Yogyakarta.
Disertasi. Universitas Gadjah Mada. Yogyakarta.
Badan Penelitian dan Pengembangan Kesehatan (Litbangkes) Kementrian Kesehatan RI.
2013. Riset Kesehatan Dasar 2013. Kementrian Kesehatan RI. Jakarta.
Ballantyne, K.N., van Oorschot, R.A.H, Mitchell, R.J. 2008. Locked nucleic acids in
PCR primers increase sensitivity and performance. Genomics 91: 301–305.
Baselga, J. 2011. Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast
Cancer. Oncologist 16: 12–19.
Bray, J., Sludden, J., Griffin, M.J., Cole, M., Verrill, M., Jamieson, D., Boddy. 2010.
Influence of pharmacogenetics on response and toxicity in breast cancer patients
treated with doxorubicin and cyclophosphamide. British J Can 102: 1003 – 1009.
Castaneda, C.A., Cortes-Funes, H., Gomez, H.L., Ciruelos, E.M. 2010. The phosphatidyl
inositol 3-kinase/akt signaling pathway in breast cancer. Cancer Metastasis Rev
29:751-759.
Chan, J.A., Krichevsky, A.M., Kosik, K.S. 2005. MicroRNA-21 is an antiapoptotic factor
in human glioblastoma cells. Cancer Res. 65: 6029-6033.
Chekhun, V.F., Kulik, G.I., Yurchenko, O.V., Tryndyak, V.P., Todor, I.N., Luniv, L.S.,
Tregubova, N.A., Pryzimirska, T.V., Montgomery, B., Rusetskaya, N.V., Pogribny,
I.P. 2006. Role of DNA hypomethylation in the development of the resistance to
doxorubicin in human MCF-7 breast adenocarcinoma cells. Can Let 231: 87–93.
De Graffenried, L.A., Fulcher, L., Friedrichs, W.E., Gru¨nwald, V., Ray, R.B., Hidalgo,
M. 2004. Reduced PTEN expression in breast cancer cells confers susceptibility to
inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15: 1510–1516.
61
62
Di Cristofano, A., Pandolfi, P.P. 2000. The multiple roles of PTEN in tumor suppression.
Cell 100: 387–390.
Fix, L.N., Shah, M., Efferth, T., Farwell, M.A., Zhang, B. 2010. MicroRNA Expression
Profile of MCF-7 Human Breast Cancer Cells and the Effect of Green Tea
Polyphenon-60. Cancer Genom Proteom 7: 261-278.
Frankel, L.B., Christoffersen, N.R., Jacobsen, A., Lindow, M., Krogh, A., Lund, A.H.
2008. Programmed Cell Death 4 (PDCD4) Is an Important Functional Target of the
MicroRNA miR-21 in Breast Cancer Cells. J Biol Chem 283:1026-1033.
Globocan-IARC. 2012. Estimated cancer incidence, mortality and prevalence worldwide
in 2012. International Agency for Research on Cancer, World Health Organization.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [12 Januari 2015].
Gonzalez-Angulo, A.M., Ferrer-Lozano, J., Stemke-Hale., K., Sahin, A., Liu, S., Barrera,
J.A., Burgues, O., Lluch, A.M., Chen, H., Hortobagyi, G.N., Mills, G.B., MericBernstam, F. 2011. PI3K Pathway Mutations and PTEN Levels in Primary and
Metastatic Breast Cancer. Mol Cancer Ther 10 (6): 1093–1101.
Gottesman, M.M., Fojo, T., Bates, S.E. 2002. Multidrug Resistance: Role of ATPDependent Transporters. Nature 2: 48-58.
Glodek, C. 1990. A History of the Michigan Cancer Foundation, the Beginnings &
Growth
of
Detroit's
Anticancer
Movement.
Michigan
Cancer
Foundation.International
Agency
for
Research
on
Cancer
(IARC).
http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf. [17 April 2014].
Hunt, K.K., Newman, L.A., Copeland, E.M., Bland, K.I. 2010. Breast dalam Schwart’s
Principle of Surgery. Mc Graw Hill. New York.
Hunz, M., Jetter, A., Warm, M., Pantke, E., Tuscher, M., Hempel, G., Jaehde, U., Untch,
M., Kurbacher, C., Fuhr, U. 2007. Plasma and tissue pharmacokinetics of epirubicin
and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced
primary breast cancer. Clin Pharmacol Ther 81: 659–668.
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D. 2011. Global cancer
statistics. CA Cancer J Clin 61: 69-90.
Juliette, J.A. and Lin, S.X. 2012. Comparison of Functional Proteomic Analyses of
Human Breast Cancer Cell Lines T47D and MCF7. PlosONE 7(2):
e31532.doi:10.1371/journal.pone.0031532.
63
Katzung, G.B., Masters, B.S., Trevor, J.A. 2009. Basic and Clinical Pharmacology.
McGraw Hill. USA. Pp.1091-1116.
Kementerian Kesehatan RI. 2010. Profil Kesehatan Indonesia Tahun 2009. Kementrian
Kesehatan RI. Jakarta.
Leslie, N.R., Batty, I.H., Maccario, H., Davidson, L., Downes, C.P. 2008. Understanding
PTEN regulation: PIP2, polarity and protein stability. Oncogene 27: 5464–5476.
Li, L.Q., Li, X.L., Wang, L., Du, W.J., Guo, R., Liang, H.H., Liu, X., Liang, D.S., Lu,
Y.J., Shan, H.L., Jiang, H.C. 2012. Matrine Inhibits Breast Cancer Growth Via miR21/PTEN/Akt Pathway in MCF-7 Cells. Cell Physiol Biochem 30: 631-641.
Livak, K.J. and Schmittgen, T.D. 2001. Analysis of Relative Gene Expression Data Using
Real-Time Quantitative PCR and the 2-∆∆CT Method. Methods 25: 402-408.
Lou, Y.H., Yang, Q.S.,Wang, F., Cui, Z., Huang, Y. 2010. MicroRNA-21 promotes the
cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas
through inhibiting the expression of PTEN protein. Intl J Mol Med 26: 819-827.
Lu, Z., Liu, M., Stribinskis, V., Klinge, C.M., Ramos, K.S., Colburn, N.H., Li, Y. 2008.
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4
gene. Oncogene 27: 4373–4379.
Lunn, M.L., Mouritzen, P., Faber, K., Jacobsen, N. 2008. MicroRNA quantitation from a
single cell by PCR using SYBR®Green detection and LNA-based primers. Nature
methods: 3-4.
Lukyanova, N.Y., Rusetskya, N.V., Tregubova, N.A., Chekhun, V.F. 2009. Molecular
Profile and Cell Cycle in MCF-7 Cells Resistant to Cisplatin and Doxorubicin. Exp
Oncol 2: 87–91
Mc Cubrey, J.A. , Steelmana, L.S., Abramsa, S.L., Leea, J.T., Changa, F., Bertranda,
F.E., Navolanica, P.M., Terrianb, D.M., Franklina, R.A., D’Assorod, A., Salisburyd,
J.L., Mazzarinoe, M.C., Stivalae, F., Libra, M. 2006. Roles of the RAF/MEK/ERK and
PI3K/PTEN/AKT Pathways in Malignant Transformation and Drug Resistance. Advan
Enzyme Regul 46: 249–279.
Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T., Patel, T. 2007.
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human
hepatocellular cancer. Gastroenterology 133:647-658.
64
Miller, T.W., Rexer, B.N., Garrett, J.T., Arteaga, C.L. 2011. Mutations in the
phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic
implications in breast cancer. Breast Cancer Res 13: 224.
Molinari, F. and Frattini, M. 2014. Functions and regulation of the PTEN gene in
colorectal cancer. Fonc 3: 1-8.
Ollson, M. and Zhivotovsky. 2011. Caspases and Cancer. Cell Death Diff. 18:1441-1449.
Papagiannakopoulos, T., Shapiro, A., Kosik, K.S. 2008. MicroRNA-21 Targets a Network
of Key Tumor-Suppressive. Pathways in Glioblastoma Cells. Cancer Res 68: 81648172.
Pelengaris, S. and Khan, M. 2006. The Molecular Biology of Cancer. Blackwell Pub.
USA. Pp 1-478.
Phin, S., Moore, M.W., Cotter, P.D. 2013. Genomic rearrangements of PTEN in prostate
cancer. Fonc 3: 1-9.
Pritchard, J.E., Dillon, P.M., Conaway, M.R., Silva, C.M., Parsons, S.J. 2012. A
Mechanistic Study of the Effect of Doxorubicin/Adriamycin on the Estrogen Response
in a Breast Cancer Model. Oncology 83(6): 305–320.
Qi, L., Bart, J., Tan, L.P., Platteel, I., Sluis, T., Huitema, S., Harms, G., Fu, L., Hollema,
H., Berg, A. 2009. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat
epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive
carcinoma. BMC Cancer 9: 163-171.
Riaz, M., van Jaarsveld, M.T.M., Hollestelle, A., Prager-van der Smissen, W.J.C., Heine,
A.A.J., Boersma, A.W.M., Liu, J., Helmijr, J., Ozturk, B., Smid, M., Wiemer, E.A.,
Foekens, J.A., Martens, W.M. 2013. miRNA expression profiling of 51 human breast
cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer
Res 15: R33-R50.
Rusetskya, N.V., Lukyanova, N.Y., Chekhun, V. F. 2009. Molecular Profile and Cell
Cycle in MCF-7 and MCF-7 /DOX Cells Exposed to Conventional and Liposomal
Form of Doxorubicin. Exp Oncol 31: 140–143.
Schwarzenbach, H., Nishida, N., Calin, G.A., Pantel, K. 2014. Clinical relevance of
circulating cell-free microRNAs in cancer. Nature Clin Oncol 11: 145-156.
Shi, Y., Moon, M., Dawood, S., McManus, B. & Liu, P.P. 2011. Mechanisms and
management of doxorubicin cardiotoxicity. Herz 36(4): 296-305.
65
Si, M.L., Zhu, S., Wu, H., Lu, Z., Wu, F., Mo, Y.Y. 2007. miR-21-mediated tumor
growth. Oncogene 26: 2799-2803.
Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., Haga, N.
2002. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival
signal. Cancer Sci 94 (1): 15-21.
Vazquez, F. and Sellers, W.R. 2000. The PTEN tumor suppressor protein: an antagonist
of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470: M21-M35.
Volinia, S., Galasso, M., Costinean, S., Tagliavini, L., Gamberoni, G., Drusco, A. 2010.
Reprogramming of miRNA networks in cancer and leukemia. Gen Res 20: 589-599.
Wang, Z.X., Lu, B.B., Wang, H., Cheng, Z.X., Yin, Y.M. 2011. MicroRNA-21 Modulates
Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN. Archive
Med Res 42: 281-290.
Weber, F.G. 2007. Molecular Mechanisms of Cancer. Springer. USA.
Weng, L.P., Smith, W.M., Dahia, P.L., Ziebold, U., Gil, E., Lees, J.A., Eng, C. 1999.
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1
arrest followed by cell death. Cancer Res 59:5808-5814.
Wind, N.S. and Holen, I. 2011.Multidrug Resistance in Breast Cancer:From In Vitro
Models to Clinical Studies. Intl J Breast Cancer. doi:10.4061/2011/967419.
Yan, L.X., Huang, X.F., Shao, Q., Huang, M.Y., Deng, L., Wu, Q.L., Zeng, Y.X. 2008.
MicroRNA miR-21 overexpression in human breast cancer is associated with
advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14:
2348–2360.
Yan, L.X., Wu, Q.N, Zhang, Y., Li, Y.Y., Liao, D.Z., Hou, J.H., Fu, J., Zeng, M.S. 2011.
Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro
migration and in vivo tumor growth. Breast Cancer Res 13: R2-R16.
Zampieri L, P Bianchi, P Ruff, P Arbuthnot. 2002. Differential modulation by estradiol of
P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast
cancer cells. Anticancer Res 22(4): 2253-2259.
Zhang, H.Y., Liang, F., Jia, Z.L., Song, S.T., Jiang, Z.F. 2013. PTEN mutation,
methylation and expression in breast cancer patients. Onc let 6: 161-168.
Zhu, S., Si, M.L., Wu, H., Mo, Y.Y. 2007. MicroRNA-21 targets the tumor suppressor
gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336.